Fuan pharmaceutical's class 3.1 new high blood pressure drug, Nabil hydrochloride, will enter the field for examination and impact the first imitation in China
-
Last Update: 2015-01-11
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
According to the public information, Nabil hydrochloride is the third generation beta blocker developed by Johnson & Johnson, which is used to treat primary hypertension and mild to moderate stable chronic heart failure According to the Research Report of Guolian securities, in 2012, the global sales of Nabil hydrochloride reached US $1 billion, which is also a potential 1 billion product in the domestic market CFDA website information shows that at present, only Fuan pharmaceutical and Jiangxi Qingfeng pharmaceutical have declared the production of the product Among them, Qingfeng pharmaceutical products are still in the drug evaluation center to carry out pharmacotoxicology, clinical and pharmaceutical evaluation, and the progress lags behind Fuan pharmaceutical Fu'an pharmaceutical is mainly engaged in the production and sales of antibiotics, and is actively transforming to specialized drugs Nabil hydrochloride is one of the most important varieties under research.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
